News

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) is pleased to announce that the Company has strengthened its European presence by appointing an additional key executive in the newly established European office to focus on capturing European business opportunities through the execution of the Company’s European strategy. The Company has appointed Dr. Rene A. Fricker […]

Dragon Pharmaceutical Inc. (“Dragon”or the “Company” (TSX: DDD; OTC BB: DRUG) today announced the financial results for the quarter ended September 30, 2005. Financial Summary Dragon reported sales of $13.34 million for the third quarter ended September 30, 2005, an increase of 82% compared to the third quarter of 2004, and 18% increase sequentially from […]

Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) today announced the appointment of Mr. Xiaochun Zhang as the General Manager of the Company’s Chinese operations. As the General Manager of our Chinese operations, Mr. Zhang is responsible for the overall operational and sales and marketing management of the Pharma and Chemical divisions. Such responsibilities will […]

Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) (“the Company”) is pleased to announce the results of the Annual Shareholders. Meeting held on August 12, 2005. There were 54,818,706 shares equaling 87.20% of the outstanding shares represented at this meeting. All of the following proposals were approved by a substantial majority of votes: Election of […]

Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD; BBSE: DRP) (“the Company”) is pleased to announce the appointment of Ernst & Young LLP (“Ernst & Young”) by its Board of Directors as the Company’s independent registered public accounting firm. In addition, the Board also approved the filing of a listing application with the American Stock […]

Dragon Pharmaceutical Inc. (“Dragon” or the “Company” (TSX: DDD; OTC BB: DRUG) announced today that, as a result of a review of its accounting policies and applicable accounting pronouncements, the Company has concluded that the reduction of a future retirement benefit obligation related to the acquisition of a land use right from an unrelated former […]

Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD; BBSE: DRP) (“the Company”) is pleased to announce that August 12, 2005 has been set as the date for the annual stockholder meeting of the Company. The annual meeting of Dragon stockholders will be held at Dragon’s corporate offices at Suite 1900, 1055 West Hastings Street, Vancouver, […]

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced that it has entered into an agreement with Suzhou Zhongkai Bio-Pharmaceuticals Company Limited (“Zhongkai”) to in-license the exclusive right to commercialize its Recombinant Human Granulocyte Colony Stimulating Factor (“rhG-CSF? product worldwide, excluding the People’s Republic of China (the “Agreement”). Using a non-mammalian cell fermentation technique […]

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG; BBSE: DRP) announces that it proposes to offer on a best efforts basis up to $25 million of its securities in a private placement to accredited investors. The type of securities, price and completion of the proposed private placement will depend on, among other things, market conditions. […]

Dragon Pharmaceuticals Inc. today announced that it has submitted a New Drug Licence application to the Chinese State Drug Administration (SDA) for the use of recombinant human erythropoietin (EPO) in surgical patients. Dragon’s EPO is currently approved and marketed for use in the treatment of anemia related to chronic renal failure in China as well […]